Coronavirus Research and Intervention
COVID-19 and the Brain
Using magnetic resonance imaging (MRI), our researchers will quantify brain abnormalities associated with COVID-19 infection.The eventual outcome will be brain markers to direct individualised treatments improving both short- and long-term outcomes from COVID-19.
Training Staff on the Front Line
Our Oxford Simulation, Training and Research Centre has been at the forefront of equipping emergency department and intensive care unit staff in the fight against coronavirus. Their years of research in developing simulation training is really paying off in the current situation.
A system developed by our researchers is being used to monitor Covid-19 patients in the John Radcliffe Hospital.It comprises wearable sensors measuring pulse rate, respiratory rate and blood oxygen saturation, combined with Bluetooth-linked tablet computers and smart alerting algorithms.
Sleep App Free for NHS Staff
Sleepio is an automated digital self-help app based on cognitive behavioural therapy for insomnia. It was developed by our sleep medicine researchers. It has been made available during the pandemic to NHS employees across the country in partnership with NHS England.
Common Medicines and Covid-19
A project involving our researchers will use national QResearch-Oxford record linkage study to understand whether drugs commonly taken for chronic conditions such as hypertension or diabetes may exacerbate or reduce the severity of COVID-19 disease.
A team from the University of Oxford and King’s College London have built a new rapidly deployable ventilator in response to the UK Government's 'ventilator challenge'. The lead medic on the project is Professor Andrew Farmery, Head of our Nuffield Division of Anaesthetics.
Impact of COVID-19 on Epilepsy
In partnership with local charity SUDEP Action, our researchers are leading a project to investigate how COVID-19 has impacted on people with epilepsy, their carers and health care workers. In particular, they are interested to assess escalation and mitigation of risk.
Drug Trial for Enhanced Respiratory Care
Researchers including Stuart McKechnie and Matthew Rowland from our Critical Care Research Group are carrying out a new drug trial aimed at treating COVID-19, funded by LifeArc. The drug could raise oxygen levels in the blood in order to improve patients' chances of recovery.
Oxford Leads Part of Major Drugs Trial
As part of the UK NIHR CATALYST Trial, researchers in Oxford will investigate whether administering the anti-inflammatory drug infliximab to patients with COVID-19 can prevent progression to respiratory failure or death. This study is a partnership with the University of Birmingham.
Effects of COVID-19 on Sleep
An international group of researchers is investigating the impact of the COVID-19 pandemic on sleep and daily rhythms in adults.This study will look at changes in sleep quality in relation to social confinement, risk of exposure to the virus, and psychological symptoms.
Motorsport Technology Keeps Clinicians Safe
Staff at our Oxford Simulation,Teaching & Research centre (OxSTaR) helped to develop this new type of aerosol shield designed by Formula One motor racing engineers. Oxford University Hospitals NHS Foundation Trust has approved its use across all four of its sites.
Helping African healthcare workers save lives
The University of Oxford's LIFE project has launched a new set of app-based training scenarios that help healthcare workers in Africa safely manage and treat cases of children with suspected COVID-19. Healthcare workers can enter a realistic 3D virtual hospital on their own smartphones.
Outcomes after COVID-19 ICU stay
Researchers are investigating the long-term health outcomes for patients who have been treated for severe COVID-19 disease in intensive care. Finding out whether these outcomes differ from those of other patients who have survived critical care will help to inform clinical practice.
COVID-19 and Guillain-Barré syndrome
Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. A new study will establish how often COVID-19 is complicated by GBS.
Associate Professor Sarosh Irani, who heads up our Autoimmune Neurology Group, has been funded by Mologic to help develop diagnostics for COVID-19. He will take blood samples from people who have had COVID-19 and derive COVID-reactive antibodies from the B cells in the blood.